-
市場
-
產品
-
資訊
-
Moo社區
-
課堂
-
查看更多
-
功能介紹
-
費用費用透明,無最低余額限制
投資選擇、功能介紹、費用相關信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 淺色
Greenwich LifeSciences, Inc. (NASDAQ:GLSI) CEO Purchases $13,840.00 in Stock
Greenwich LifeSciences, Inc. (NASDAQ:GLSI) CEO Purchases $13,840.00 in Stock
Greenwich LifeSciences, Inc. (NASDAQ:GLSI – Get Rating) CEO Snehal Patel purchased 1,000 shares of the firm's stock in a transaction on Friday, December 2nd. The stock was acquired at an average price of $13.84 per share, with a total value of $13,840.00. Following the completion of the purchase, the chief executive officer now owns 2,722,886 shares of the company's stock, valued at approximately $37,684,742.24. The purchase was disclosed in a filing with the SEC, which can be accessed through the SEC website.
Snehal Patel also recently made the following trade(s):
Get Greenwich LifeSciences alerts:- On Wednesday, November 2nd, Snehal Patel purchased 2,000 shares of Greenwich LifeSciences stock. The stock was acquired at an average price of $8.79 per share, with a total value of $17,580.00.
- On Friday, October 14th, Snehal Patel purchased 3,000 shares of Greenwich LifeSciences stock. The stock was acquired at an average price of $9.75 per share, with a total value of $29,250.00.
- On Friday, October 7th, Snehal Patel acquired 2,000 shares of Greenwich LifeSciences stock. The stock was purchased at an average price of $9.72 per share, with a total value of $19,440.00.
- On Friday, October 7th, Snehal Patel acquired 2,000 shares of Greenwich LifeSciences stock. The stock was purchased at an average price of $9.72 per share, with a total value of $19,440.00.
- On Thursday, September 29th, Snehal Patel acquired 1,000 shares of Greenwich LifeSciences stock. The stock was purchased at an average price of $9.23 per share, with a total value of $9,230.00.
Greenwich LifeSciences Stock Performance
Shares of NASDAQ:GLSI opened at $13.70 on Friday. Greenwich LifeSciences, Inc. has a 52-week low of $6.82 and a 52-week high of $36.00. The business has a 50-day moving average price of $10.71 and a 200-day moving average price of $9.55.
Greenwich LifeSciences (NASDAQ:GLSI – Get Rating) last announced its quarterly earnings data on Monday, November 14th. The company reported ($0.18) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.19) by $0.01. Analysts forecast that Greenwich LifeSciences, Inc. will post -0.57 EPS for the current year.Institutional Inflows and Outflows
Several institutional investors have recently modified their holdings of GLSI. Pura Vida Investments LLC acquired a new stake in Greenwich LifeSciences during the third quarter worth about $179,000. Walleye Capital LLC acquired a new stake in Greenwich LifeSciences during the second quarter worth about $90,000. Goldman Sachs Group Inc. acquired a new stake in Greenwich LifeSciences during the second quarter worth about $104,000. Occudo Quantitative Strategies LP acquired a new stake in Greenwich LifeSciences during the second quarter worth about $199,000. Finally, Cubist Systematic Strategies LLC acquired a new stake in Greenwich LifeSciences during the second quarter worth about $130,000. 8.06% of the stock is currently owned by hedge funds and other institutional investors.
About Greenwich LifeSciences
(Get Rating)
Greenwich LifeSciences, Inc, a clinical stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is the GP2, an immunotherapy, which has completed Phase IIb clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery.
Read More
- Get a free copy of the StockNews.com research report on Greenwich LifeSciences (GLSI)
- Can Pfizer, Johnson & Johnson Continue Outperforming the Index?
- This Is Why Daktronics Fell 40% In One Day
- Is It Time To Throw In The Towel On Gamestop?
- Why You Should Avoid Carvana Even if it Avoids Bankruptcy
- Are Investors Hearing The End Of Spotify's Downtrend?
Receive News & Ratings for Greenwich LifeSciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Greenwich LifeSciences and related companies with MarketBeat.com's FREE daily email newsletter.
Greenwich LifeSciences, Inc. (NASDAQ:GLSI – Get Rating) CEO Snehal Patel purchased 1,000 shares of the firm's stock in a transaction on Friday, December 2nd. The stock was acquired at an average price of $13.84 per share, with a total value of $13,840.00. Following the completion of the purchase, the chief executive officer now owns 2,722,886 shares of the company's stock, valued at approximately $37,684,742.24. The purchase was disclosed in a filing with the SEC, which can be accessed through the SEC website.
格林威治生命科學公司(納斯達克代碼:GET Rating)首席執行官斯內哈爾·帕特爾在12月2日星期五的一筆交易中購買了該公司1,000股股票。該股的收購均價為每股13.84美元,總價值為13,840.00美元。收購完成後,首席執行官現在擁有2,722,886股公司股票,價值約37,684,742.24美元。此次收購是在提交給美國證券交易委員會的一份檔案中披露的,該檔案可以通過美國證券交易委員會網站.
Snehal Patel also recently made the following trade(s):
斯內哈爾·帕特爾最近還進行了以下交易:
- On Wednesday, November 2nd, Snehal Patel purchased 2,000 shares of Greenwich LifeSciences stock. The stock was acquired at an average price of $8.79 per share, with a total value of $17,580.00.
- On Friday, October 14th, Snehal Patel purchased 3,000 shares of Greenwich LifeSciences stock. The stock was acquired at an average price of $9.75 per share, with a total value of $29,250.00.
- On Friday, October 7th, Snehal Patel acquired 2,000 shares of Greenwich LifeSciences stock. The stock was purchased at an average price of $9.72 per share, with a total value of $19,440.00.
- On Friday, October 7th, Snehal Patel acquired 2,000 shares of Greenwich LifeSciences stock. The stock was purchased at an average price of $9.72 per share, with a total value of $19,440.00.
- On Thursday, September 29th, Snehal Patel acquired 1,000 shares of Greenwich LifeSciences stock. The stock was purchased at an average price of $9.23 per share, with a total value of $9,230.00.
- 11月2日星期三,斯內哈爾·帕特爾購買了2,000股格林威治生命科學公司的股票。該股是以每股8.79美元的平均價格收購的,總價值為17,580.00美元。
- 10月14日,星期五,斯內哈爾·帕特爾購買了3,000股格林威治生命科學公司的股票。該股是以每股9.75美元的平均價格收購的,總價值為29,250.00美元。
- 10月7日,星期五,斯內哈爾·帕特爾收購了格林威治生命科學公司的2000股股票。這只股票是以每股9.72美元的平均價格購買的,總價值為19,440.00美元。
- 10月7日,星期五,斯內哈爾·帕特爾收購了格林威治生命科學公司的2000股股票。這只股票是以每股9.72美元的平均價格購買的,總價值為19,440.00美元。
- 9月29日,星期四,Snehal Patel收購了1,000股Greenwich LifeSciences股票。該股是以每股9.23美元的平均價格購買的,總價值為9,230.00美元。
Greenwich LifeSciences Stock Performance
格林威治生命科學公司股票表現
Shares of NASDAQ:GLSI opened at $13.70 on Friday. Greenwich LifeSciences, Inc. has a 52-week low of $6.82 and a 52-week high of $36.00. The business has a 50-day moving average price of $10.71 and a 200-day moving average price of $9.55.
納斯達克:GLSI上週五開盤報13.7美元。Greenwich LifeSciences,Inc.的股價為6.82美元,為52周低點,52周高點為36.00美元。該業務的50日移動均線價格為10.71美元,200日移動均線價格為9.55美元。
Institutional Inflows and Outflows
機構資金流入和流出
Several institutional investors have recently modified their holdings of GLSI. Pura Vida Investments LLC acquired a new stake in Greenwich LifeSciences during the third quarter worth about $179,000. Walleye Capital LLC acquired a new stake in Greenwich LifeSciences during the second quarter worth about $90,000. Goldman Sachs Group Inc. acquired a new stake in Greenwich LifeSciences during the second quarter worth about $104,000. Occudo Quantitative Strategies LP acquired a new stake in Greenwich LifeSciences during the second quarter worth about $199,000. Finally, Cubist Systematic Strategies LLC acquired a new stake in Greenwich LifeSciences during the second quarter worth about $130,000. 8.06% of the stock is currently owned by hedge funds and other institutional investors.
幾家機構投資者最近調整了對GLSI的持股。Pura Vida Investments LLC在第三季度收購了Greenwich LifeSciences的新股份,價值約17.9萬美元。Walleye Capital LLC在第二季度收購了Greenwich LifeSciences價值約9萬美元的新股份。高盛股份有限公司在第二季度收購了格林威治生命科學公司價值約10.4萬美元的新股份。Occudo Quantity Strategy LP在第二季度收購了Greenwich LifeSciences的新股份,價值約19.9萬美元。最後,立體主義系統戰略有限責任公司在第二季度收購了格林威治生命科學公司價值約13萬美元的新股份。8.06%的股票目前由對沖基金和其他機構投資者持有。
About Greenwich LifeSciences
關於格林威治生命科學
(Get Rating)
(獲取評級)
Greenwich LifeSciences, Inc, a clinical stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is the GP2, an immunotherapy, which has completed Phase IIb clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery.
格林威治生命科學公司是一家臨床階段的生物製藥公司,專注於為乳腺癌和其他表達HER2/neu的癌症開發新型癌症免疫療法。它的主要候選產品是GP2,這是一種免疫療法,已經完成了IIb期臨床試驗,以防止以前接受過手術的患者的乳腺癌復發。
Read More
閱讀更多內容
- Get a free copy of the StockNews.com research report on Greenwich LifeSciences (GLSI)
- Can Pfizer, Johnson & Johnson Continue Outperforming the Index?
- This Is Why Daktronics Fell 40% In One Day
- Is It Time To Throw In The Towel On Gamestop?
- Why You Should Avoid Carvana Even if it Avoids Bankruptcy
- Are Investors Hearing The End Of Spotify's Downtrend?
- 免費獲取StockNews.com關於格林威治生命科學(GLSI)的研究報告
- 輝瑞、強生能否繼續跑贏該指數?
- 這就是為什麼達科電子在一天內下跌了40%
- 是時候在Gamestop上認輸了嗎?
- 為什麼你應該避免Carvana,即使它可以避免破產
- 投資者是否聽到了Spotify下跌趨勢的終結?
Receive News & Ratings for Greenwich LifeSciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Greenwich LifeSciences and related companies with MarketBeat.com's FREE daily email newsletter.
接受《格林威治生活科學日報》的新聞和評級-在下面輸入您的電子郵件地址,通過MarketBeat.com的免費每日電子郵件時事通訊接收對Greenwich LifeSciences和相關公司的最新新聞和分析師評級的每日簡要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
風險及免責聲明
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能,分享給你的好友吧